Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q4 2012 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$2.88M-$2.88MderivedN/M vs Q4 2011 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$3,703,189N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,417,777N/M ended Dec 31, 2012 · filed Mar 29, 2013 · 88 d after period end